文章预览
HAIWEN NEWS Haiwen acted for Genor Biopharma in the first reverse takeover announced by a Hong Kong-listed pre-revenue biotech company 2024年10月7日， 嘉和生物 （06998.HK ） 发布交易公告，宣布与 亿腾医药 达成合并协议。根据交易公告，本次交易是 嘉和生物 向成熟且全面整合的生物制药公司迈出的关键一 步，预期将为 嘉和生物 及 亿腾医药 带来互补及协同效应，并为合并完成后经扩大集团的可持续发展奠定良好的基础。 On 7 October 2024, Genor Biopharma (06998.HK) announced that it had entered into a merger agreement with Edding Group . According to the announcement, this transaction is a key step for Genor Biopharma to transform into a developed and fully integrated biopharmaceutical company, and is expected to bring complementary and synergetic effects to both Genor Biopharma and Edding Group , and lay an important foundation for the sustainable development of the e
………………………………
